Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024) · Cardiovascular Therapeutics · n=0
Studienprofil
- Design
- narrative systematic review of randomized controlled trials comparing heparin and bivalirudin anticoagulation in patients undergoing PCI for STEMI, NSTEMI, and unstable angina (Tangshan Gongren Hospital, China; Wuhan University; Harvard T.H. Chan)
- Stichprobengröße (n)
- —
- Intervention
- Bivalirudin (synthetic hirudin-derived direct thrombin inhibitor) anticoagulation during PCI
- Komparator
- Unfractionated heparin (standard reference anticoagulant)
- Primärer Endpunkt
- Composite of efficacy (ischemic events) and safety (bleeding events) outcomes from major RCTs
- Primäres Ergebnis
- Bivalirudin generally associated with lower bleeding rates than heparin in PCI for ACS; ischemic outcome equivalence varies by trial and ACS subtype; review reinforces clinical equipoise in some patient subgroups; demonstrates how synthetic hirudin-derivative pharmacology is studied via rigorous Phase-III pathways
- Follow-up-Dauer
- Variable across cited RCTs (typically 30 days to 1 year)
- PMID
- 39749045
Wichtigste Ergebnisse
- Bivalirudin generally associated with lower bleeding than heparin in PCI for ACS
- Trial-by-trial heterogeneity in ischemic-event outcomes
- Bivalirudin is a synthetic hirudin derivative (Angiomax) with established FDA approval
- Demonstrates the drug-regulatory pathway distinct from K040187 device pathway
- Useful pedagogical reference for explaining FDA drug vs FDA device distinctions
Einschränkungen
- Narrative synthesis without quantitative meta-analysis
- Cited RCTs span multiple decades and PCI eras
- Generalization across STEMI / NSTEMI / unstable angina subgroups limited
- No new primary data
- Not directly applicable to whole-leech hirudotherapy
Klinische Implikationen
Wang 2024 provides contemporary clinical-pharmacology context for bivalirudin — the synthetic hirudin derivative — within interventional cardiology. For ASH, the review serves as a regulatory and educational reference for distinguishing FDA-approved drug indications (synthetic hirudin derivatives) from the FDA K040187 device indication (whole-leech therapy). No direct US hirudotherapy clinical-practice implications.
Verwandte Studien
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
Fuchs J, Cannon CP (1995)
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW (2009)
Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps
Harun A, Kruer RM, Lee A, Boahene K, Byrne PJ, Richmon JD (2018)
Impact of Bivalirudin on Ischemia/Reperfusion Injury in Patients with Reperfused STEMI Assessed by Cardiac Magnetic Resonance
Zhang Y, Zou Z, Xu B, Chen B, Ge H, Ding S, Pu J (2024)